Sedighi Abdolazim, Hamed Ehsan Akbari, Mohammadian Kamal, Behnood Sepideh, Kalaghchi Bita
Mahdieh Diagnostic and Medical Center, Hamedan, Iran E-mail :
Asian Pac J Cancer Prev. 2013;14(12):7381-3. doi: 10.7314/apjcp.2013.14.12.7381.
Male breast cancer accounts for less than 1% of all cancer in men and only around 1% of all diagnosed breast cancer. Despite a significant raise in the last 25 years, it still remains a rare disease.
We conducted a retrospective study from 2004-2011 with 21 male breast cancer patients. We aimed to analyze the epidemiologic data (age, personal and family history), tumor characteristics (size, histological type, location, TNM stage, receptors), surgery, adjuvant chemotherapy and radiation therapy, hormonal therapy and survival (relapse, follow up, death) who reffered to our center with breast cancer.
The median age was 49.2±14.2 years (range 30-83 years). A family history of breast cancer was noted in four cases. The main clinical complaint was a retroareolar mass in 85.7%of patients (n=18). Histologically, 85.7% (n=18)were invasive ductal carcinoma and 4.7% (n=1) had ductal carcinoma in situ and 9.4% (n=2) had mixed histology including invasive medullary and ductal carcinoma. Hormonal therapy was delivered to 16 cases (76.1%) due to ER or PR positivity. During median follow up of 30 months (3-84 month), distant metastases were evident in 4 cases (19%). During the follow-up period, only one patient died due to metastatic disease. The mean time to recurrence detection was 30 months.
The percentage of cases of male breast cancer is very low compared to breast cancer in females, explaining why very few investigations have been conducted in Iran. Limited coverage in the literature make gender-specific findings difficult so future research of this entity involving multi-institutional cooperation and longer follow up is essential to provide new insights about the biological and clinical factors of this rare cancer.
男性乳腺癌占男性所有癌症的比例不到1%，仅占所有确诊乳腺癌的1%左右。尽管在过去25年中有显著上升，但它仍然是一种罕见疾病。
我们对2004年至2011年期间的21例男性乳腺癌患者进行了一项回顾性研究。我们旨在分析转诊至我们中心的乳腺癌患者的流行病学数据（年龄、个人和家族史）、肿瘤特征（大小、组织学类型、位置、TNM分期、受体）、手术、辅助化疗和放疗、激素治疗以及生存情况（复发、随访、死亡）。
中位年龄为49.2±14.2岁（范围30 - 83岁）。4例有乳腺癌家族史。主要临床症状为乳晕后肿块，占患者的85.7%（n = 18）。组织学上，85.7%（n = 18）为浸润性导管癌，4.7%（n = 1）为导管原位癌，9.4%（n = 2）为混合组织学类型，包括浸润性髓样癌和导管癌。由于雌激素受体（ER）或孕激素受体（PR）阳性，16例（76.1%）接受了激素治疗。中位随访30个月（3 - 84个月）期间，4例（19%）出现远处转移。在随访期间，仅1例患者因转移性疾病死亡。复发检测的平均时间为30个月。
与女性乳腺癌相比，男性乳腺癌的病例百分比非常低，这解释了为什么伊朗进行的相关研究很少。文献报道有限使得难以得出针对性别的研究结果，因此未来涉及多机构合作和更长随访时间的该领域研究对于提供有关这种罕见癌症的生物学和临床因素的新见解至关重要。
